Regulation of the proinflammatory effects of Fas ligand (CD95L).
about
Antioxidant c-FLIP inhibits Fas ligand-induced NF-kB activation in a phosphatidylinositol 3-kinase/Akt-dependent mannerNatural selection of tumor variants in the generation of "tumor escape" phenotypesCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaFas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data.Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cellsThe naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathwayCytotoxic proteins and therapeutic targets in severe cutaneous adverse reactionsImmunosuppressive strategies that are mediated by tumor cellsPhase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.Transforming growth factor beta (TGF-beta) and inflammation in cancer.Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapyEnvironmentally induced autoimmune diseases: potential mechanismsFas and Fas ligand in gut and liver.Use of preferentially replicating bacteria for the treatment of cancer.Molecular mechanisms of liver fibrosis in HIV/HCV coinfectionp38-mediated regulation of an Fas-associated death domain protein-independent pathway leading to caspase-8 activation during TGFbeta-induced apoptosis in human Burkitt lymphoma B cells BL41.Hepatocyte death: a clear and present danger.The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesisFas receptor-mediated apoptosis: a clinical application?Fas ligand and the fate of antitumour cytotoxic T lymphocytes.Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.Apoptosis as a mechanism for liver disease progression.All in the head: obstacles for immune rejection of brain tumours.Dissecting Fas signaling with an altered-specificity death-domain mutant: requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation.Cell death and immune privilege.Principles of tumor immunosurveillance and implications for immunotherapy.Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.Mammary gland involution as an immunotherapeutic target for postpartum breast cancer.Fas and Fas ligand expression in cystic fibrosis airway epitheliumHarnessing the immunomodulatory properties of Sertoli cells to enable xenotransplantation in type I diabetes.Disorders of lung matrix remodeling.Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer.Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival.Fas ligand triggers pulmonary silicosisBy altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucomaRoles of apoptosis in airway epithelia.T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis.Human melanoma cells do not express Fas (Apo-1/CD95) ligandCombined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report.A vision of cell death: Fas ligand and immune privilege 10 years later.
P2860
Q23909852-AB625F94-A715-4C5B-8DFE-BC00ECA8B8A1Q24551158-289AD42E-A962-4C56-A560-9A12841AE4FCQ24679736-B3E0C3DC-6DAA-443D-A74A-F9C657F20C0FQ25256768-E9FF73A3-E054-4CDA-9FDA-1D1D79E143B9Q26996742-502808E1-4237-48F2-B2C1-9E93B5BFA039Q27321306-26579FC2-8477-497B-9DDA-4DD3FAC29152Q28395744-98F8258D-B492-42B6-AB0A-1E1D5A72B425Q29636247-3967FFA0-1394-46B2-B871-7FF446EDDC03Q33340438-B64C096F-401E-4977-924E-E99B01B8AB9AQ33712568-E7A30DE1-06F6-4660-8E3C-70B9F165E6D1Q33723734-B65414C6-CCDE-4E8A-A353-1059F462C600Q33741188-07AE3127-3D9C-480B-823B-0B5EF9F1014BQ33860215-9CCED987-E4DD-4EBA-83EA-B875FAF01D53Q33895307-44C1FE5E-DF25-42DE-B5C4-C4099F91B47AQ33907429-52A00401-A25C-4B9E-A6CD-50B665829289Q33948252-61696F15-6653-4FC8-9CA9-FAB5E661FF0AQ34147508-23DBE2C3-2390-4CC0-A587-BA902B3430CEQ34411509-0C45142D-06EC-462D-BC86-A6DEAD1B3D07Q34495634-94029E5A-0591-4D27-8BD0-B9335CDAB7A6Q34579773-522E0523-6E04-4283-8482-2021F6CCC53FQ34592338-FA2903FF-429C-47C2-B9FB-1BDD516BB0A9Q34764471-89716C43-41F0-4E72-98C2-ED85BF07481AQ34842204-AF357D1F-92F7-4EF3-B446-FBE5878DE62EQ34986210-55D82201-2661-4DA4-89BD-50B9B8B74538Q34993208-3F0222DC-AA12-4ECE-B1FB-2FED20EC6ABAQ35043113-0C2B26FF-2311-4B57-ABA1-F7E9C0372973Q35045303-670BC14B-8DA8-4DA9-8107-3B1C9E4E4E67Q35186471-8C8321CF-00AC-4016-8AF3-C0E2A86B761EQ35573072-D2445FC9-4E2B-42F1-8F4A-D07A1222124FQ35578236-86F42388-AC1B-4B1A-9EC6-B19F4A0B015CQ35628568-B8F38CB5-98AB-42C4-8219-86B4DFC634D5Q35783456-AEDECF00-BB36-4A1E-818A-602F240A2CAAQ36368504-7E71013A-A00F-424F-8EA0-D46E69878922Q36369388-E77FC5CA-D28C-4E69-88A4-F9C033EA8C53Q36370392-3A8BF595-1BAD-4D55-A4EC-9BBEC6F97824Q36378783-30157609-07F9-4F9A-A855-C4ED6A6F4551Q36399210-8D5678B7-D956-4716-ADD8-61498B1380ACQ36454464-2E5D031E-A3C1-4D15-A2A3-29F0F2C349FDQ36501180-270D072F-A9A0-43E6-9582-2395837C033CQ36593770-1E0F5361-98BC-4D5C-8ACE-1B1B6E65867D
P2860
Regulation of the proinflammatory effects of Fas ligand (CD95L).
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Regulation of the proinflammatory effects of Fas ligand (CD95L).
@en
type
label
Regulation of the proinflammatory effects of Fas ligand (CD95L).
@en
prefLabel
Regulation of the proinflammatory effects of Fas ligand (CD95L).
@en
P2093
P1433
P1476
Regulation of the proinflammatory effects of Fas ligand (CD95L).
@en
P2093
P304
P356
10.1126/SCIENCE.282.5394.1714
P407
P577
1998-11-01T00:00:00Z